IMPACT OF RSV IN OWR AREA AND RESULTS OF PROPHYLAXIS WITH
PALIVIZUMAB
E.
Narbona L¨®pez; J. Garrido Garc¨ªa; M. Molina Hoya; R. Santana Delgado; E. M.
Sena Ruiz.; M J Miras Baldo
Neonatology
Service, Universitary Hospital ¡°San Cecilio¡±, Granada, Spain
Objective: To
study the incidence of RSV in the area attended by owr hospital
(Universitary Hospital ¡°San Cecilio¡± in Granada) which cover the south part
of Granada province in Andalucia, Spain, and the evolution of a group of
high risk infants who received prophylaxis with Palivizumab.
Methods: We
recolected the stories of all the children hospitalized because of low
respiratory infection from birth to 18 months in winter of 1999-2000 and
2000-2001. Also we followed a group of 43 high risk infants who received
minthly dosis of Palivizumab during the winter of 2000-2001. This group was
compound of 25 male and 18 female with an age range of 6-18 months at the
beginning of prophylaxis. These infants were selected for this group
because of prematurity, neonatal respiratory pathology or familiar risk
factors. Gestational age range: 25-34 weeks. Birth weight range: 840-2500g.
Severe respiratory pathology during the neonatal period: 21 of then.
|
Gestational age (weeks)
|
Birth weight (gr)
|
Sex
|
Neonatal
|
|
25-28
|
9
|
<1000g
|
7
|
Male
|
25
|
Mechanical Ventilation
|
21
|
|
29-30
|
14
|
1000-1500
|
12
|
|
31-32
|
8
|
1500-2000
|
16
|
Female
|
18
|
O2 >1week
|
37
|
|
33-34
|
12
|
2000-2500
|
8
|
Results:1
Impact in owr area: Between 261 infants from hospitalized in owr service
because of LRI, 115 were RSV positive. RSV infections peak begins in
January and finishes in May with a maximum in March which is also the month
of maximum incidence of LRI. 2 Evolution of infants who receive prophylaxis
with Palivizumab: Although they were high risk infants only 4 of 43 needed
to be hospitalized by RSV infection during the period they received
prophylaxis, in front of a range of 25-30% of hospitalized in the group of
high risk infants without prophylaxis. From these four ones, only 2 were
hospitalized because of RSV infection, and both of then were very high risk
infants with encefalopathy and prematurity. Other 2 infants hospitalized by
other causes were infected in hospital by RSV, but their evolution were
better than other RSV positive without prophylaxis.
Conclusions: RSV
is a mayor agent of LRI in infants of owr area which causes a high
hospitalization incidence. The seasonal distribution of cases are similar
to other studies throuth Europe. Prophylaxis with Palivizumab seems to be a
good weapon to protect high risk infants in order to reduce the incidence
of hospitalization in this group.